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Abstract
With imprecise definitions, inexact measurement tools, and flawed study execution, our clinical science often lags
behind bedside experience and simply documents what appear to be the apparent faults or validity of ongoing
practices. These impressions are later confirmed, modified, or overturned by the results of the next trial. On the other
hand, insights that stem from the intuitions of experienced clinicians, scientists and educators—while often
neglected—help place current thinking into proper perspective and occasionally point the way toward formulating
novel hypotheses that direct future research. Both streams of information and opinion contribute to progress. In this
paper we present a wide-ranging set of unproven ‘out of the mainstream’ ideas of our FCCM faculty, each with a
defensible rationale and holding clear implications for altering bedside management. Each proposition was designed
deliberately to be provocative so as to raise awareness, stimulate new thinking and initiate lively dialog.
Keywords: Microcirculation, Resuscitation, Shock, Sepsis, Ventilator-induced lung injury, Personalized medicine,
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Background
In our current era of evidence based medicine, empirical
results of clinical trials are most highly valued as the foun-
dation of our knowledge, while experience-based and
eminence-based opinions, often published as commentar-
ies, editorials, essays and letters, take a ‘back seat’. Yet,
some insights that stem from the intuitions of experienced
clinicians, scientists and educators help place current
thinking into proper perspective and point the way toward
formulating the novel hypotheses that direct future
investigative scientific efforts. In fact, while technical inno-
vations, experimental observations and statistical meta-
analyses often lead clinical practice, at other times the
opposite is true; conflicting data from imperfect studies
generate lingering confusion and doubt. With imprecise
definitions, study executions and measurements, our clin-
ical science often lags behind practical experience and
simply documents what appear to be the faults or validity
of ongoing practice. As we have experienced in recent de-
cades, progress made with these blunt tools for advancing
the care of the individual can be vexingly slow and inexact.
Better study designs, targeted biomarkers, integrative as
opposed to reductionist thinking and ‘big data’ capabilities
hold genuine promise to personalize critical care—but
clearly, we are not there yet.
In most meeting formats, faculty presenters rely on
established principles and an examination of what has
recently been published or confirmed to present their
ideas. Debates and panel discussions either help bring
about consensus (always comforting and sometimes dan-
gerous) and/or highlight genuine differences of opinion.
As in the prior two Future of Critical Care Medicine
(FCCM) meetings, one of our sessions took a radical de-
parture from those traditional approaches. What follows
is a wide-ranging set of unproven ‘out of the main-
stream’ ideas of our faculty, each with a defensible ra-
tionale and holding clear implications for altering
bedside management. The intent of this provocative for-
mat was to stimulate thinking and interchange, and per-
haps to point toward new directions for productive
research, concept development, and eventual application
to improved care for the critically ill.
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Daniel De Backer: Release tissue nitric oxide for
improving microvascular perfusion
Background
Tissue perfusion can be altered even when cardiac out-
put and arterial pressure remain within reasonable goals.
Alterations in microvascular perfusion have been shown
to occur in sepsis and septic shock [1], as well as in a
variety of other conditions (cardiogenic shock, trauma,
ischemia reperfusion injury, etc.). These are character-
ized by the close proximity of non-perfused vessels to
perfused vessels, leading to microvascular shunting and
increased oxygen diffusion distances. The severity and
the duration of such microcirculatory disturbances relate
to mortality and development of organ dysfunction [2].
Several mechanisms have been implicated in the devel-
opment of these alterations, including loss of communi-
cation between vascular segments, impaired endothelial
reactivity, alterations in red and white blood cell rheol-
ogies, alteration in endothelial glycocalyx, platelet aggre-
gation and microthrombosis.
Given the characteristics of microvascular alterations
and the mechanisms potentially implicated, it seems lo-
gical to try to recruit the microcirculation more than to
increase the flow within the already perfused vessels. In
addition, an ideal intervention should help reverse the
implicated pathological mechanisms, not only improve
microvascular perfusion.
Among the suggested interventions, certain vasodilatory
agents have been proposed. Nitroglycerin was the first to
be introduced. After initial promising results of a pilot trial
including eight patients [3], a confirmatory randomized
trial found no difference in the changes in microvascular
perfusion between patients receiving nitroglycerin and
placebo. Several factors may explain this negative result,
including a potential decrease in nitric oxide (NO) gener-
ation from nitroglycerin, as it requires efficient aldehyde
dehydrogenase type 2 that may be inhibited in sepsis [4].
Another point of attack is to exploit local release of
NO at the microcirculatory level to promote targeted
vasodilation. There are two known ways to boost NO at
the endothelial level, one through endothelial NO syn-
thase and the other through nitrite reduction.
For the first reaction (Arginine + O2 = > Citrullin +
NO], oxygen and an effective endothelial NO synthase
are required. Interestingly, endothelial NO synthase may
be dysfunctional in sepsis or in ischemia/reperfusion in-
jury, due to a decrease in one of its mandatory cofactors,
tetrahydrobiopterin. In an ovine model of septic shock,
administration of tetrahydrobiopterin improved micro-
vascular perfusion, vascular permeability, organ function
and survival time [5]. Similarly, administration of vita-
min C, which increases tetrahydrobiopterin availability,
also improves microvascular perfusion in sepsis, in a
pathway that depends on endothelial NO synthase [6].
The second reaction converts nitrite into NO
(Hb[Fe2+] + NO2
− +H+ =>NO+Hb[Fe3+] + OH−). This re-
action is accelerated in the presence of deoxyhemoglobin,
as opposed to oxyhemoglobin [7]. As a result, it mostly
occurs in the microcirculation in the hypoperfused capil-
laries of metabolically active areas where oxygen satur-
ation is low.
Idea
Administer nitrites with the hope that they could be
converted into NO in the most vulnerable parts of the
microcirculation.
Can Ince: Better resuscitation fluids for shock can
be devised that improve perfusion, boost oxygen
delivery and reduce inflammation
Background
Resuscitation from cardiocirculatory compromise is aimed
at correcting decreased microcirculatory perfusion by im-
proving blood flow and consequently sustaining tissue
oxygenation. Shock is associated with a compromise in
oxygen transport to the tissues, resulting in organ dys-
function. If left uncorrected this condition results in organ
injury and, ultimately, in organ failure. The current ap-
proach to resuscitation is to target systemic perfusion by
administration of vasoactive compounds and non-oxygen
carrying salty solutions with or without larger colloid mol-
ecules to ensure a longer presence in the circulation.
The primary challenge in fluid therapy is to ensure that
sufficient oxygen gets transported to the microcirculation
and ultimately to the tissue cells. Here conventional fluids
fail on two counts: The first shortcoming of conventional
fluids is their hemorheological effect. Lower viscosity re-
duces the ability of the diluted blood to recruit unfilled ca-
pillaries (for which the viscosity of hematocrit is needed).
This reduces the functional capillary density, creating lar-
ger diffusion distances between oxygen-carrying red blood
cell-filled capillaries and the respiring cells of organ tissue.
The second potential shortcoming of resuscitation fluids
is their poor oxygen solubility (less than 3% compared to
hemoglobin (Hb)), which decreases the oxygen carrying
capacity of blood. Indeed, several experimental studies dir-
ectly measuring microcirculatory oxygen availability fol-
lowing fluid resuscitation in models of shock have shown
repeatedly that although fluids are capable of correcting
systemic hemodynamic variables such as blood pressure
and cardiac output, they can be ineffective in improving
microcirculatory perfusion and tissue oxygenation in vul-
nerable organs such as the kidney. The only therapeutic
modality to improve oxygen levels in the microcirculation
is provided by blood transfusions [8]. However, there is
much clinical reluctance to administer blood due its po-
tential harmful side effects, such as the rise in free Hb and
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the potential immunological response of the host to hom-
ologous blood transfusions.
An alternative to homologous blood transfusion is of-
fered by Hb-based oxygen carriers (HBOCs), and many
such compounds have been developed over the past de-
cades. Experimentally these compounds have been
shown to improve microcirculatory oxygen availability in
models of shock [9]. Although conceptually appealing,
their clinical introduction has been mired by problems.
These include the vasopressor effect caused by their high
affinity for NO, causing vasoconstriction. Different types
of HBOCs have been developed with the aim of reducing
this vasopressor effect, but these compounds have not
shown clinical efficacy. The reason for this lack of suc-
cess are several; a) at the bedside, there is an inadequate
monitoring methodology to assess the need for tissue
oxygenation to indicate the need for HBOCs over simply
giving fluids; b) the p50s of HBOCs ranges from 5 mmHg
(where oxygen will stay stuck to the Hb) to p50s in the
range of that of natural Hb where oxygen can be easily
lost and not reach the parenchymal cells in need of oxy-
gen; c) inadequately designed clinical trials have gener-
ated little knowledge about when, how much and to
what target.
From a different perspective, HBOCs conventionally
have been administered as stand-alone drugs, whereas
they could potentially be used as an adjunct to conven-
tional fluid therapy to increase the oxygen-carrying cap-
acity of volume therapy. Besides improving perfusion
and oxygenation, resuscitation fluids should also be ef-
fective in reducing and controlling inflammation. In pur-
suit of this idea, investigations have been conducted to
examine the potential anti-inflammatory and anti-
oxidant effects of infused fluids (e.g., starches) as well as
attaching molecules such as CO and glutathione to
HBOC to control inflammation and oxidative stress [10].
From a therapeutic hemodynamic point of view, there-
fore, resuscitation requires reversal of shock, sepsis and
hypovolemia. The first objective is to ensure microcircu-
latory and tissue perfusion; second, to restore perfusion
is accompanied by a restoration of adequate tissue oxy-
gen availability; and finally, to ensure that the cellular
constituents of the microcirculation and parenchymal
cells are protected from injury associated with the in-
flammatory molecules and oxidative and nitrosative
stress associated with shock and reperfusion.
The two categories of resuscitation fluid in current use
are blood and non-oxygen carrying crystalloid or colloid
solutions. Each of these has been shown to have adverse
effects due to composition and uncertainty about how to
titrate these solutions under different conditions of
hypovolemia and shock, where too much and too little
are both considered harmful. As already mentioned, the
ultimate target for administering the optimal volume
resides in the microcirculation for which handheld mi-
croscopy could be a potential tool to optimally adminis-
ter resuscitation [11]. However, fluid content needs also
to be more personalized, matching the specific needs of
individual patients.
In doing so, a broth of molecules must be configured
that addresses the specific type of fluid needed to target
the specific physiological compartment of the individual
patient in need of resuscitation. The compartments
which can be identified include intracellular, interstitial
and intravascular. Intracellular hydration requires a crys-
talloid solution with glucose, whereas interstitial hydra-
tion needs any physiologic crystalloid solution.
Intravascular hypovolemia is best addressed by a colloid
solution to ensure sustained filling of the vasculature.
Resuscitation fluid should ideally also carry anti-
inflammatory and oxygen carrying agents to completely
meet the goals of resuscitation.
When considering the ultimate composition of such
an ideal resuscitation fluid, one is reminded of the bene-
ficial effects of the chicken soup cure for common in-
flammatory conditions [12]. It carries nutrients, provides
hydration, is isotonic (if you don’t add salt of course)
and is anti-inflammatory. Looking at chicken soup as a
pharmacological agent for resuscitation, therefore, it
seems like an ideal candidate. What is missing in
chicken soup, however, is an oxygen-carrying agent such
as a HBOC. Such a ‘pink chicken soup’ would hydrate,
fill the vasculature (colloid effect), offer anti-inflammatory
properties and promote the transport of oxygen to the tis-
sues (the pink stuff).
Idea
A ‘pink chicken soup’ that addresses the deficiencies of
our current options may indeed be a candidate for the
optimal shock resuscitation fluid of the future.
John J. Marini: We should address the forgotten but
crucial vascular side of ventilator-induced lung injury
Background
Although ventilator-induced lung injury (VILI) is un-
doubtedly a complex process that is influenced by many
factors, the great majority of investigative attention has
been directed to airspace mechanics, as exemplified by
tidal volume, plateau pressure, PEEP and driving pres-
sure. Yet, because the fragile alveolus serves as the inter-
face between gas and blood, and because the stresses
applied to the airway epithelium also impact vascular
endothelium, the potential for vascular pressures and
flows to impact the development and/or evolution of
VILI also deserves close consideration.
Mechanical forces that tear the delicate alveolar-
capillary membrane can originate on either side of the
boundary. Adverse ventilatory patterns applied to
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previously healthy lungs not only cause proteinaceous
edema, but also neutrophil aggregation and hemorrhage
[13]. In the supine position, hemorrhagic edema
forms preferentially in dependent areas [14, 15]. This
proclivity is not subtle, and has been corroborated by the
work of investigators using diverse injury models [16].
The tendency for hemorrhage to occur preferentially in
the most dependent regions of the lung may have several
explanations. One compelling reason to expect micro-
vascular disruption to occur there is that the mechanical
stresses applied by the tidal inflation cycle are greatly
amplified at the interface of opened and closed lung tis-
sues. An admittedly oversimplified geometrical argument
indicates that strains at high airway pressure are several
times as great as that experienced in the free walls of the
open alveolus.
It is somewhat counter-intuitive that tissue disruption
should occur in areas in which transmural stretching
forces (as defined by plateau pressure minus pleural
pressure) are weakest. That is to say, “alveolar stretch” is
greatest in the non-dependent regions, which are rela-
tively spared both the hemorrhagic infiltrate and most
signs of inflammation. The tendency for hemorrhage to
occur preferentially in the most dependent regions of
the lung may have several explanations. The local
mechanical driving power [17] may far exceed that
experienced in non-dependent zones. Although under-
studied, surfactant depletion and inflammatory weak-
ening of the interstitial structure could amplify the
impact of such forces, whereas other changes of the
microenvironment (e.g., flooding by edema) could ab-
rogate the mechanical stresses experienced in distal
lung units.
Interactions between vascular pressure and ventila-
tion suggest strongly that closer attention should be
paid to interventions that impact vascular pressures,
flows, and resistances when high inflation pressures are
in use. Because microvascular stresses appear to be a
potent cofactor in the development of pulmonary
edema as well as lung damage resulting from an injuri-
ous pattern of ventilation, the clinician managing acute
lung injury must reconcile the competing objectives of
ensuring adequate oxygen delivery and minimizing ad-
verse effects. If increased pre-alveolar microvascular
pressure accentuates a tendency for VILI, attempts to
raise cardiac output may have unintended conse-
quences. On the other hand, taking steps to reduce
oxygen consumption demands could benefit the lung
by reducing the pressure gradient developed across the
microvasculature. Reduction in the demands for cardiac
output and ventilation could dramatically reduce the
tendency for VILI even when using patterns that gener-
ate similar values for peak, end-expiratory, and driving
alveolar pressures.
Idea
Restrain pulmonary vascular flows and pressures by low-
ering oxygen demand to further reduce the incidence
and severity of VILI.
Mervyn Singer: Outcomes and therapeutic responses
to ICU care can be predicted for septic patients
Background
Septic critically ill patients may be predestined to survive
or die, perhaps explaining the failure of the many trials
testing interventions to interrupt the natural course of
sepsis. Indeed, we have not shown yet that we can “beat
nature”; most progress over the past 20 years relates to
inflicting less iatrogenic harm to the patient, not improv-
ing response and accelerating natural healing. If this
analysis is correct, we inadvertently may simply prolong
the course to death among those destined not to survive,
at high personal and economic costs.
Using modern bioanalytical techniques, numerous stud-
ies have demonstrated the predictive potential of bio-
markers, metabolomes, and proteomes to differentiate
among eventual survivors and non-survivors of sepsis,
even at a very early stage. Three interesting studies con-
ducted from blood samples taken upon presentation to
the emergency room have demonstrated that inflamma-
tory cytokines (IL-6, IL-10) [18], cardiac troponin-T [19],
and metabolomes characterizing fatty acid transport, glu-
coneoenesis, and the citric acid cycle [20] can point the
way to the outcome that time would eventually reveal.
Similar prognostication regarding the likely response
to treatment is also possible using both inflammatory
biomarkers or physiological indicators. For example,
stratification on the basis of inflammatory biomarkers
may help direct immune modulatory therapy. Steroids
given to septic animals predicted to die proved bene-
ficial; steroids given to those projected to survive did
not [21]. Reflections of these experimental observa-
tions were observed retrospectively using physiological
parameters in the CORTICUS hydrocortisone trial
[22]. Despite the increased risks of superinfection that
the corticosteroids imposed, those septic patients with
systolic blood pressures persisting below 90 mmHg
after one day of appropriate fluids and vasopressors
experienced a significant reduction of mortality risk if
given hydrocortisone.
Another important controversy regarding pharmaco-
therapy of sepsis concerns the wisdom of beta blockade.
In a randomized clinical trial, esmolol showed the distinct
potential to reduce mortality risk, but only for patients
who were both tachycardic and receiving high-dose nor-
epinephrine therapy at 24 hours, reflecting a similar result
as obtained with experimental sepsis in rats [23]. In rats
with septic physiology, esmolol treatment appeared to
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benefit animals predicted not to survive and to harm the
predicted survivors.
Such examples show that using both physiological and
molecular indicators may allow us to predict the even-
tual outcome of life-threatening sepsis at an early time
point and thereby select our treatments more effectively.
Such predictive ability would not only improve the de-
sign of our clinical trials, but also help to select therapies
for the individual that hold the most potential for effect-
ive and humane care.
Idea
Predict potential survivors and non-survivors of sepsis
causing critical illness at an early stage and treat these
patient categories differently.
Frank Van Heren: Novel adaptive designs of
clinical trials improve their efficiency and value
Background
In clinical research, randomization among alternatives is
central to progress because associations and inferences
from observational studies may not prove causative.
Unfortunately, as currently conducted, our large ran-
domized trials often conflict and generally have proven
disappointing in the critical care setting [24]. The most
likely explanations include imprecise definitions, inexact
or inappropriate controls, and an inability to control or
account for all influential variables, as important synergis-
tic interactions produce emergent phenomena that are
not accounted for in the trial design. Inability to recruit
sufficient numbers of appropriate candidate patients over
a reasonable time drags out the data collection process
(often attenuating relevance to current practices) or termi-
nates many such investigative efforts.
One innovative approach to randomized trial design is
to depart from rigid one-to-one randomization and into
adaptive allocation to the study limbs in accordance with
relative response as the study progresses. Under this
paradigm, if a subgroup starts to do better with one
treatment, more future patients are allocated to that
limb to confirm or refute that trend and accelerate the
pace of the investigation. Frequent looks at the develop-
ing data are implicit when taking this approach.
The platform trial, an efficient strategy for simultan-
eously and sequentially evaluating numerous treatments
within the framework of a single study, has been proposed
by Berry and colleagues [25] as a tool with which to deter-
mine their relative worth among a heterogeneous popula-
tion. This approach recognizes the imprecision of our
current definitions and classifications, as it explicitly rec-
ognizes that targeted populations and treatment responses
may be heterogeneous, even when careful measures are
taken to be appropriately selective. Such a strategy departs
from that of the traditional trial, which assumes itself to
be testing the efficacy of a single intervention in a gener-
ally homogeneous population. A unique aspect of this par-
ticular “adaptive” approach is that the platform trial can
be carried out over the long-term—even perpetually, so
long as there are suitable treatments requiring evaluation.
The number of treated groups or specific treatments may
change over time, with specific individual treatment
groups removed for demonstrated efficacy or harm. Such
capability departs from our current “fixed randomization”
approach in which the entire trial is stopped for success,
futility, or harm based on the effects of a single experi-
mental treatment. We must change our clinical trial para-
digm so that we recognize current limitations. Should we
embrace the principle that most major public health prob-
lems should be the subject of perpetual global adaptive
trials?
Idea
Continuous and adaptive clinical trials with interchange-
able parts should be the research standard.
Martin Westphal: Disruption of sleep patterns and
circadian rhythms is an important and
addressable cause of varied ICU morbidities
Background
Melatonin, a hormone produced in the pineal gland, is
well-known to influence the state of wakefulness. It is syn-
thesized and released under the regulation of the clock
genes concentrated and expressed in the suprachiasmatic
nucleus of the brain. Promoted by darkness, release of
melatonin peaks during health in the early morning hours
and plummets just before awakening. In the ICU, that nat-
ural diurnal rhythm is seriously disrupted by internal fac-
tors related to the critical illness as well as by external
factors such as light, noise, continuously infused sedatives,
stress, and varied medical treatments [26]. Disrupted sleep
architecture and cumulative sleep deficits are contributors
to lingering delirium [27], now thought to be a major
contributor to delays in extubation and rehabilitation.
Selected clinical trials have shown the ability of exogen-
ously administered melatonin to help address these issues
[28]. In concept, better sleep should speed recovery and
help prevent the post-ICU syndrome.
Less well appreciated by intensive care unit practitioners
is the intriguing body of research evidence indicating that
melatonin may have other important roles to play during
serious illness and recovery. The spectrum of melatonin’s
effects unrelated to sleep ranges from antioxidant proper-
ties to antimicrobial activity and immunomodulation [29].
Neuroprotective [30], antioxidant, infection inhibiting,
and anti-neoplastic actions have been reported [29]. Given
melatonin’s central importance as a regulatory hormone,
restoring its normal daily influence and timing of its con-
centration could make a major contribution to ICU care.
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Melatonin plays a pivotal role in the regulation of circa-
dian rhythm, not only for the brain, but for the activities
of other vital organs as well. Virtually free of deleterious
side effects, melatonin is inexpensive to administer and of-
fers a variety of potentially beneficial actions. It should
therefore be routinely used in both the acute and chronic
phases of serious illness.
Idea
Melatonin should be administered to all critically ill pa-
tients able to receive it.
Paul Wischmeyer: Non-invasive metabolism
monitoring aids in personalizing critical illness
interventions
Background
Prediction, early intervention, and monitoring of pro-
gress are essential to personalize critical care manage-
ment. Treatments and doses applicable to one stage or
severity of critical illness may be inappropriate to apply
at a later one. An important challenge is to monitor the
patient’s pre-illness, acute, chronic, and recovery stage
and status by noninvasive means. Metabolic changes re-
flect breakdown, rebuilding, and innate cellular function-
ing during the illness course. One currently available
methodology determines the relationship of two carbon
isotopes in exhaled gas to determine stage and status:
the 13CO2/
12CO2 ratio [31]. C
12, the far more common
form in the healthy individual, is easier to break down
than C13 for energy production, and C12 is freely exhaled
as 12CO2. In contrast, C
13 is incorporated into acute
phase proteins and is not exhaled at usual concentra-
tions during the inflammatory state. Consequently, at
the very onset of an acute inflammatory illness, the ratio
of 13CO2/
12CO2 decreases in the exhaled gas [32]. In
fact, detectable changes in the ratio precede the clinically
detectable signs of infection. While individual point de-
terminations of breath analyses do not correlate well
with the inflammatory status, trends in the 13CO2/
12CO2
ratio clearly do.
In clinical studies, down-trending of the 13CO2/
12CO2
ratio in exhaled gas significantly precedes alterations in
leukocytes, body temperature, and clinical suspicion of
such developing infections, such as pneumonia. Con-
versely, reversal of the trend in the ratio indicates that
inflammation is receding and that a stage transition is
underway, perhaps indicating the emergence of different
nutritional requirements. Such trend analyses appear to
be both sensitive and specific. Other potential applica-
tions of the 13CO2/
12CO2 ratio monitoring include de-
termination of underfeeding or overfeeding status.
Metabolism monitoring may hold therapeutic potential
not only for the acute state but also for the rehabilitation
phase [33]. It is known that healthy mitochondria
primarily utilize fatty acids to produce energy. In con-
junction with the other standard physiological and bio-
chemical indicators, monitoring of fat oxidation rate
versus carbohydrate oxidation rate may help characterize
tissue vitality and rehabilitation progress, and thereby
help shape targeted exercise/nutritional/hormonal
programs to aid faster recovery from critical illness.
Idea
Metabolism monitoring should be used to diagnose
infection, determine the phase of critical illness, and
guide post-ICU rehabilitation.
Conclusion
The seven ideas presented here are intended to be con-
ceptually provocative and are not yet grounded in defini-
tive scientific evidence. Nonetheless, the authors hope
that they provide points of departure for thought, dis-
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